Frozen shoulder trial: At GP practice and community setting (ACCorD)

Adhesive Capsulitis CORticosteroid and Dilation randomised controlled trial: a feasibility study in primary care

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14209869

Enrollment

Registered

2022-12-20

Start date

2023-02-14

Completion date

Unknown

Last updated

2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen shoulder Musculoskeletal Diseases Adhesive capsulitis of shoulder

Interventions

Participants will be randomly allocated on a 1:1 ratio to CSI&HD versus CSI alone, stratified by recruiting centre. Allocation will be at the time of the injection and follow up will be continued for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults with frozen shoulder, defined as: 1. Aged 18 years and older 2. Loss of passive external rotation of at least 50% compared with the contralateral side 3. Presence of symptoms for at least 4 weeks 4. Plain radiographs demonstrating the absence of glenohumeral osteoarthritis or other pathology

Exclusion criteria

Exclusion criteria: 1. Recurrent ipsilateral frozen shoulder 2. Presentation following breast cancer or local radiotherapy 3. Known rotator cuff tear 4. Long-term systemic corticosteroid use, or previous ipsilateral shoulder CSI within 12 months

Design outcomes

Primary

Measure	Time frame
1. The rate of eligible participants presenting to the MSK hubs (Screening logs) 2. The proportion of eligible participants that clinicians are willing to recruit (Baseline visit 1, questionnaires) 3. The proportion of eligible participants that are randomised (Baseline visit 1/Intervention visit 2, questionnaires) 4. Adherence to the study protocol and attrition at 6 months (All visits (1-6), questionnaires) 5. Data completeness using traditional clinical reporting forms and routine data sources.	—

Measure

Time frame

1. The rate of eligible participants presenting to the MSK hubs (Screening logs) 2. The proportion of eligible participants that clinicians are willing to recruit (Baseline visit 1, questionnaires) 3. The proportion of eligible participants that are randomised (Baseline visit 1/Intervention visit 2, questionnaires) 4. Adherence to the study protocol and attrition at 6 months (All visits (1-6), questionnaires) 5. Data completeness using traditional clinical reporting forms and routine data sources.

—

Secondary

Measure	Time frame
1. Upper limb function will be assessed using the Oxford Shoulder Score (OSS) (Baseline visit 2, Follow up at visit 3-6; questionnaires) 2. Quality of life will be assessed using the Euroquol (EQ-5D-5L) (Baseline visit 2, Follow up at visit 3-6; questionnaires) 3. Upper limb range of motion (Baseline visit 2, Follow up at visit 3-6; Face to face study visit measurement and also from photos of upper limb submitted by participants) 4. Resource use (Baseline visit 2, Follow up at visit 3-6; questionnaires)	—

Measure

Time frame

1. Upper limb function will be assessed using the Oxford Shoulder Score (OSS) (Baseline visit 2, Follow up at visit 3-6; questionnaires) 2. Quality of life will be assessed using the Euroquol (EQ-5D-5L) (Baseline visit 2, Follow up at visit 3-6; questionnaires) 3. Upper limb range of motion (Baseline visit 2, Follow up at visit 3-6; Face to face study visit measurement and also from photos of upper limb submitted by participants) 4. Resource use (Baseline visit 2, Follow up at visit 3-6; questionnaires)

—

Countries

United Kingdom

Contacts

Public ContactBina Shah

accord-bjh@qmul.ac.uk+44 2078823384

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026